B cell and B cell-related pathways for novel cancer treatments.

Tokunaga, Ryuma; Naseem, Madiha; Lo, Jae Ho; Battaglin, Francesca; Soni, Shivani; Puccini, Alberto; Berger, Martin Dave; Zhang, Wu; Baba, Hideo; Lenz, Heinz-Josef (2019). B cell and B cell-related pathways for novel cancer treatments. Cancer treatment reviews, 73, pp. 10-19. Elsevier 10.1016/j.ctrv.2018.12.001

Text 1-s2.0-S0305737218301993-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (981kB)

B cells are recognized as the main effector cells of humoral immunity which suppress tumor progression by secreting immunoglobulins, promoting T cell response, and killing cancer cells directly. Given these properties, their anti-tumor immune response in the tumor micro-environment (TME) is of great interest. Although T cell-related immune responses have become a therapeutic target with the introduction of immune checkpoint inhibitors, not all patients benefit from these treatments. B cell and B cell-related pathways (CCL19, -21/CCR7 axis and CXCL13/CXCR5 axis) play key roles in activating immune response through humoral immunity and local immune activation via tertiary lymphoid structure (TLS) formation. However they have some protumorigenic works in the TME. Thus, a better understanding of B cell and B cell-related pathways is necessary to develop effective cancer control. In this review, we summarize recent evidences regarding the roles of B cell and B cell-related pathways in the TME and immune response and discuss their potential roles for novel cancer treatment strategies.

Interest & Impact

Downloads

1 since deposited on 08 Mar 2019
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item